|Day's Range||165.32 - 166.75|
|52 Week Range||158.54 - 209.22|
|PE Ratio (TTM)||170.37|
|Dividend & Yield||0.91 (0.55%)|
|1y Target Est||N/A|
The chief executive of Shire has questioned investors' valuation of his company, arguing the potential of a number of promising drugs has yet to be factored into its share price. Flemming Ornskov also ...
The Zacks Analyst Blog Highlights: Merck, Eli Lilly, Celgene, Gilead Sciences and Shire